Procept Biorobotics (PRCT)

$67.45

-1.96

(-2.82%)

Market is closed - opens 7 PM, 25 Jul 2024

Performance

  • $67.25
    $70.17
    $67.45
    downward going graph

    0.3%

    Downside

    Day's Volatility :4.15%

    Upside

    3.87%

    downward going graph
  • $24.83
    $77.00
    $67.45
    downward going graph

    63.19%

    Downside

    52 Weeks Volatility :67.75%

    Upside

    12.4%

    downward going graph

Returns

PeriodProcept BioroboticsSector (Health Care)Index (Russel 2000)
3 Months
29.02%
7.1%
0.0%
6 Months
46.38%
8.2%
0.0%
1 Year
87.1%
10.3%
0.0%
3 Years
60.82%
14.0%
-19.9%

Highlights

Market Capitalization
3.6B
Book Value
$5.14
Earnings Per Share (EPS)
-2.12
Wall Street Target Price
75.43
Profit Margin
-66.13%
Operating Margin TTM
-62.08%
Return On Assets TTM
-20.31%
Return On Equity TTM
-47.29%
Revenue TTM
156.3M
Revenue Per Share TTM
3.21
Quarterly Revenue Growth YOY
82.5%
Gross Profit TTM
37.1M
EBITDA
-104.2M
Diluted Eps TTM
-2.12
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-1.93
EPS Estimate Next Year
-1.49
EPS Estimate Current Quarter
-0.56
EPS Estimate Next Quarter
-0.53

Analyst Recommendation

Buy
    86%Buy
    13%Hold
    0
    0%Sell
Based on 15 Wall street analysts offering stock ratings for Procept Biorobotics(by analysts ranked 0 to 5 stars)
Based on 15 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
13
13
13
Hold
2
2
2
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 11.83%

Current $67.45
Target $75.43

Company Financials

FY19Y/Y Change
Revenue
6.2M
-
Net Income
-42.7M
-
Net Profit Margin
-691.41%
-
FY20Y/Y Change
Revenue
7.7M
↑ 25.09%
Net Income
-58.3M
↑ 36.58%
Net Profit Margin
-754.89%
↓ 63.48%
FY21Y/Y Change
Revenue
34.5M
↑ 346.72%
Net Income
-62.4M
↑ 7.09%
Net Profit Margin
-180.96%
↑ 573.93%
FY22Y/Y Change
Revenue
75.0M
↑ 117.6%
Net Income
-93.6M
↑ 50.01%
Net Profit Margin
-124.76%
↑ 56.2%
FY23Y/Y Change
Revenue
136.2M
↑ 81.55%
Net Income
-105.9M
↑ 13.16%
Net Profit Margin
-77.76%
↑ 47.0%
Q4 FY22Q/Q Change
Revenue
23.8M
↑ 16.85%
Net Income
-31.3M
↑ 35.39%
Net Profit Margin
-131.66%
↓ 18.04%
Q1 FY23Q/Q Change
Revenue
24.4M
↑ 2.64%
Net Income
-27.7M
↓ 11.5%
Net Profit Margin
-113.53%
↑ 18.13%
Q2 FY23Q/Q Change
Revenue
33.1M
↑ 35.65%
Net Income
-25.3M
↓ 8.73%
Net Profit Margin
-76.38%
↑ 37.15%
Q3 FY23Q/Q Change
Revenue
35.1M
↑ 6.04%
Net Income
-24.6M
↓ 2.62%
Net Profit Margin
-70.14%
↑ 6.24%
Q4 FY23Q/Q Change
Revenue
43.6M
↑ 24.16%
Net Income
-27.5M
↑ 11.7%
Net Profit Margin
-63.11%
↑ 7.03%
Q1 FY24Q/Q Change
Revenue
44.5M
↑ 2.2%
Net Income
-26.0M
↓ 5.62%
Net Profit Margin
-58.28%
↑ 4.83%
FY19Y/Y Change
Total Assets
62.0M
-
Total Liabilities
205.8M
-
FY20Y/Y Change
Total Assets
126.0M
↑ 103.2%
Total Liabilities
308.9M
↑ 50.06%
FY21Y/Y Change
Total Assets
337.0M
↑ 167.54%
Total Liabilities
69.9M
↓ 77.36%
FY22Y/Y Change
Total Assets
309.3M
↓ 8.22%
Total Liabilities
112.3M
↑ 60.52%
FY23Y/Y Change
Total Assets
404.7M
↑ 30.84%
Total Liabilities
124.0M
↑ 10.43%
Q4 FY22Q/Q Change
Total Assets
309.3M
↓ 4.54%
Total Liabilities
112.3M
↑ 8.7%
Q1 FY23Q/Q Change
Total Assets
284.5M
↓ 8.04%
Total Liabilities
111.3M
↓ 0.82%
Q2 FY23Q/Q Change
Total Assets
272.4M
↓ 4.22%
Total Liabilities
116.5M
↑ 4.68%
Q3 FY23Q/Q Change
Total Assets
421.1M
↑ 54.57%
Total Liabilities
121.8M
↑ 4.48%
Q4 FY23Q/Q Change
Total Assets
404.7M
↓ 3.9%
Total Liabilities
124.0M
↑ 1.8%
Q1 FY24Q/Q Change
Total Assets
382.9M
↓ 5.39%
Total Liabilities
118.9M
↓ 4.12%
FY19Y/Y Change
Operating Cash Flow
-43.8M
-
Investing Cash Flow
43.2M
-
Financing Cash Flow
26.5M
-
FY20Y/Y Change
Operating Cash Flow
-48.3M
↑ 10.33%
Investing Cash Flow
-233.0K
↓ 100.54%
Financing Cash Flow
106.8M
↑ 302.5%
FY21Y/Y Change
Operating Cash Flow
-57.3M
↑ 18.6%
Investing Cash Flow
-592.0K
↑ 154.08%
Financing Cash Flow
262.1M
↑ 145.49%
FY22Y/Y Change
Operating Cash Flow
-80.4M
↑ 40.2%
Investing Cash Flow
-2.7M
↑ 348.14%
Financing Cash Flow
3.6M
↓ 98.62%
Q4 FY22Q/Q Change
Operating Cash Flow
-25.2M
↑ 26.81%
Investing Cash Flow
-866.0K
↓ 42.8%
Financing Cash Flow
-1.3M
↓ 269.63%
Q1 FY23Q/Q Change
Operating Cash Flow
-35.9M
↑ 42.72%
Investing Cash Flow
-5.3M
↑ 516.51%
Financing Cash Flow
380.0K
↓ 128.83%
Q2 FY23Q/Q Change
Operating Cash Flow
-28.3M
↓ 21.12%
Investing Cash Flow
-5.4M
↑ 0.62%
Financing Cash Flow
2.4M
↑ 539.47%

Technicals Summary

Sell

Neutral

Buy

Procept Biorobotics is currently in a neutral trading position according to technical analysis indicators.

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Procept Biorobotics
Procept Biorobotics
14.71%
46.38%
87.1%
60.82%
60.82%
Stryker Corporation
Stryker Corporation
0.26%
9.14%
17.02%
29.18%
60.08%
Boston Scientific Corp.
Boston Scientific Corp.
0.32%
27.83%
48.37%
76.85%
85.1%
Edwards Lifesciences Corp.
Edwards Lifesciences Corp.
-4.53%
18.22%
-5.16%
-20.15%
22.77%
Abbott Laboratories
Abbott Laboratories
1.68%
-4.62%
-5.02%
-10.26%
21.89%
Medtronic Plc
Medtronic Plc
-0.55%
-6.78%
-10.11%
-37.56%
-21.67%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Procept Biorobotics
Procept Biorobotics
53.06
NA
NA
-1.93
-0.47
-0.2
NA
5.14
Stryker Corporation
Stryker Corporation
39.05
39.05
2.92
11.95
0.19
0.07
0.01
50.33
Boston Scientific Corp.
Boston Scientific Corp.
66.04
66.04
1.8
2.33
0.09
0.05
NA
13.56
Edwards Lifesciences Corp.
Edwards Lifesciences Corp.
37.48
37.48
5.19
2.76
0.21
0.12
NA
11.82
Abbott Laboratories
Abbott Laboratories
32.78
32.78
5.99
4.66
0.15
0.06
0.02
22.31
Medtronic Plc
Medtronic Plc
28.77
28.77
1.52
5.2
0.07
0.04
0.04
38.29
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Procept Biorobotics
Procept Biorobotics
Buy
$3.6B
60.82%
53.06
-66.13%
Stryker Corporation
Stryker Corporation
Buy
$130.2B
60.08%
39.05
16.03%
Boston Scientific Corp.
Boston Scientific Corp.
Buy
$115.5B
85.1%
66.04
12.05%
Edwards Lifesciences Corp.
Edwards Lifesciences Corp.
Buy
$52.4B
22.77%
37.48
23.01%
Abbott Laboratories
Abbott Laboratories
Buy
$180.8B
21.89%
32.78
13.65%
Medtronic Plc
Medtronic Plc
Buy
$101.8B
-21.67%
28.77
11.36%

Insights on Procept Biorobotics

  • Increasing Revenue

    Revenue is up for the last 16 quarters, 1.19M → 44.53M (in $), with an average increase of 19.8% per quarter

  • Increasing Net Profit

    Netprofit is up for the last 2 quarters, -27.50M → -25.95M (in $), with an average increase of 6.0% per quarter

Institutional Holdings

  • FMR Inc

    14.64%
  • Cpmg Inc

    10.37%
  • Vanguard Group Inc

    8.26%
  • BlackRock Inc

    6.41%
  • T. Rowe Price Investment Management,Inc.

    5.72%
  • AllianceBernstein L.P.

    3.86%

Company Information

based in silicon valley, procept biorobotics is a privately held surgical robotics company enabling better patient care by developing transformative solutions in urology. with an initial focus on benign prostatic hyperplasia (bph), the company’s first product, the aquabeam system delivering aquablation therapy, is the world’s first commercially available minimally invasive surgical robot providing autonomous tissue removal to safely and effectively treat bph. aquablation therapy offers predictable and reproducible outcomes, independent of prostate anatomy or surgeon experience.

Organization
Procept Biorobotics
Employees
626
CEO
Dr. Reza Zadno Ph.D.
Industry
Healthcare

FAQs